title: A phase II study of hydrocodone for cough in advanced cancer.
abstract: OBJECTIVE
  Cough is a common symptom in advanced cancer. The use of hydrocodone as an antitussive has not been studied previously in this setting. This study evaluates hydrocodone for cough in advanced cancer
  
  
  METHODS
  The results presented are from a phase II study with dose titration.
  
  
  METHODS
  Palliative medicine program in a tertiary referral center
  
  
  METHODS
  25 consecutive patients with cough from irreversible causes, on a stable opioid regimen for the prior 24 hours, and no previous or current use of hydrocodone for cough.
  
  
  METHODS
  5 mg hydrocodone was administered twice daily. The dose was then titrated daily (maximum: 60 mg/24 h), if needed, until a > or = 50 percent improvement of the frequency of cough was achieved and then maintained for three consecutive days.
  
  
  METHODS
  Cough severity, frequency, complications, and hydrocodone side effects.
  
  
  RESULTS
  20 persons (10 women and 10 men) completed study evaluation. Median age was 63 years (range: 42-82). Nine patients had lung cancer and seven had lung or pleura metastases; 19 patients had at least 50 percent improvement of their cough frequency. The median best response was 70 percent improvement in the cough frequency (range: 50-90 percent). Median hydrocodone dose associated with the best response was 10 mg/day (range: 5-30 mg/day). Cough severity, frequency, associated symptoms and complications, and activities of daily living improved significantly. Side effects of hydrocodone (dry mouth, nausea, and drowsiness) were tolerable and rated as mild.
  
  
  CONCLUSIONS
  Hydrocodone is effective and safe to treat cough in advanced cancer A starting dose of 10 mg per day in divided doses seems effective. Dose escalation may be required. Most improved within one day.
authors.affiliation: Harry R. Horvitz Center for Palliative Medicine (a World Health Organization Demonstration Project in Palliative Medicine), Cleveland Clinic Taussig Cancer Center, Ohio, USA.
authors.forename: Jade
authors.initials: J
authors.lastname: Homsi
authors.forename: Declan
authors.initials: D
authors.lastname: Walsh
authors.forename: Kristine A
authors.initials: KA
authors.lastname: Nelson
authors.forename: Nabeel
authors.initials: N
authors.lastname: Sarhill
authors.forename: Lisa
authors.initials: L
authors.lastname: Rybicki
authors.forename: Susan B
authors.initials: SB
authors.lastname: Legrand
authors.forename: Mellar P
authors.initials: MP
authors.lastname: Davis
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000996:Antitussive Agents / Q000627:therapeutic use*; D003371:Cough / Q000188:drug therapy* / Q000209:etiology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006853:Hydrocodone / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D010997:Pleural Neoplasms / Q000150:complications / Q000188:drug therapy*; D018709:Statistics, Nonparametric
chemical_list: D000996:Antitussive Agents; D006853:Hydrocodone